

ABSTRACT

Chemotherapy is one way of cervical cancer treatment. The main problem in the prevention of cancer is the high cost of chemotherapy and long time therapy. The high cost of cervical cancer treatment not only cause economic loss for patients, but also for families and governments. Since the enactment of the National Health Insurance on 2014, the payment method in the hospital is use Indonesia Case Base Groups (INA-CBG's). This research is an observational analytic research. The data were taken prospectively from the claim file of cervical cancer patients who received chemotherapy. The aimed of this study is to know the difference between real cost with INA-CBG's rates of cervical cancer patients who get chemotherapy. Based on 60 episodes during the period of May 2015 - June 2015 it was found that there was no significant difference between real cost and INA CBG's rates on mild chemotherapy level both in treatment class 3,2,1 and on moderate chemotherapy level in treatment class 3. There is a significant difference between the real cost and INA CBG'rates at the level of moderate chemotherapy in treatment class 2. Based on the multivariate correlation analysis, it was found that the cost of medicines and medical goods and the cost of non operative medical measures is a factor affecting the real cost.

Keywords: INA CBG's, Real Cost, Cervical Cancer.